HRMY Key Statistics, Chart & Performance
The current stock price of HRMY is 37.47 USD. In the past month the price increased by 12.49%. In the past year, price increased by 9.31%.
HRMY Latest News, Press Relases and Analysis
HRMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.06 | 999.15B | ||
| JNJ | JOHNSON & JOHNSON | 20.07 | 501.88B | ||
| MRK | MERCK & CO. INC. | 11.43 | 249.91B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.13 | 108.57B | ||
| ZTS | ZOETIS INC | 19.36 | 54.10B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.35 | 22.18B | ||
| VTRS | VIATRIS INC | 5.12 | 13.75B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.01 | 10.98B | ||
| CORT | CORCEPT THERAPEUTICS INC | 92.66 | 8.58B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.41B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.39B |
Related stock screener links
About HRMY
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). The company also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Company Info
HARMONY BIOSCIENCES HOLDINGS
630 W Germantown Pike, Suite 215
Plymouth Meeting PENNSYLVANIA 19462 US
CEO: John C. Jacobs
Employees: 246
Phone: 14845399800
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you describe the business of HARMONY BIOSCIENCES HOLDINGS?
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). The company also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Can you provide the latest stock price for HARMONY BIOSCIENCES HOLDINGS?
The current stock price of HRMY is 37.47 USD. The price decreased by -3.38% in the last trading session.
What is the dividend status of HARMONY BIOSCIENCES HOLDINGS?
HRMY does not pay a dividend.
How is the ChartMill rating for HARMONY BIOSCIENCES HOLDINGS?
HRMY has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is the GICS sector and industry of HRMY stock?
HARMONY BIOSCIENCES HOLDINGS (HRMY) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does HARMONY BIOSCIENCES HOLDINGS have?
HARMONY BIOSCIENCES HOLDINGS (HRMY) currently has 246 employees.
Can you provide the upcoming earnings date for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) will report earnings on 2026-02-23, after the market close.
HRMY Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to HRMY. When comparing the yearly performance of all stocks, HRMY is one of the better performing stocks in the market, outperforming 75.98% of all stocks.
HRMY Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to HRMY. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues.
HRMY Financial Highlights
Over the last trailing twelve months HRMY reported a non-GAAP Earnings per Share(EPS) of 3.18. The EPS increased by 50.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.48% | ||
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| Debt/Equity | 0.18 |
HRMY Forecast & Estimates
17 analysts have analysed HRMY and the average price target is 47.11 USD. This implies a price increase of 25.71% is expected in the next year compared to the current price of 37.47.
For the next year, analysts expect an EPS growth of 29.83% and a revenue growth 20.8% for HRMY